← ANALYST RATINGS · TIPRANKS

Fulgent Genetics (FLGT): analyst forecast and price target

$19.81 −7.17% close 16.10.26 · market cap $587M · Healthcare · Medical - Diagnostics & Research IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

0 Buy1 Hold0 Sell

Ratings of 1 analysts in the last 3 months · top analysts only

12-month forecast

$19.00−4.1% downside

Based on 1 price targets given in the last 3 months, the average target is $19.00, the highest $19.00, the lowest $19.00. The average is −4.1% from the last price of $19.81.

$15.00$20.00$25.00$30.00Jan 26AprJulOctJan 27AprJulOctHigh$19.00Average$19.00Low$19.00
Highest target $19.00 Average target $19.00 Lowest target $19.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% Piper Sandler $15.00 → $19.00+26.7% Hold −4.1% Reiterated 04.08.26on TipRanks 07:45 +3.5%next day +0.1% · 5 days +2.5%
Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% UBS $35.00 → $22.00−37.1% Buy +11.1% Reiterated 02.03.26on TipRanks 09:15 −7.4%next day −2.0% · 5 days +6.0%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Fulgent Genetics

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%
1 year Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%
2 years Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%

Most profitable

3 months Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%
1 year Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%
2 years Lu Li★★★★★★★★★★UBS · #5185
Hits 80%8 of 10 Average return +11.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $22.02 (−13.7%); now: $19.00 at $19.81 (−4.1%).

$19.00$20.00$21.00$22.00Sep 15Oct 1Oct 15Top analysts$19.00Average target$19.00Price$19.81

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

001121Oct 251Nov1Dec1Jan 26FebMarApr1May1Jun2Jul2Aug2Sep1Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy000000
Hold112221
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.65 (from $-0.65 to $-0.65). Last quarter: $-0.58.

Sales

Next quarter’s sales estimate — $86M (from $86M to $86M). Last quarter: $85M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Fulgent Genetics

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

Data from the stock’s TipRanks forecast page, read 111 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗